Lowers the risk of myocardial infarction, myocardial revascularization procedures, and…. ANDA 76056, held by Aurobindo Pharma USA. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 76056 (Pravastatin Sodium), held by Aurobindo Pharma USA, was first approved by FDA on Apr 24, 2006, with 12 approved supplements and 0 published complete response letters.
Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 24, 2006 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Feb 24, 2025 | Supplement 25Labeling · Standard review | Approved | None posted |
| Feb 16, 2021 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jan 23, 2017 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 30, 2015 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 30, 2012 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 4, 2012 | Supplement 11Labeling | Approved | None posted |
| Sep 27, 2011 | Supplement 10Labeling | Approved | None posted |
| Jan 8, 2010 | Supplement 8Manufacturing | Approved | None posted |
| Oct 5, 2007 | Supplement 7Labeling | Approved | None posted |
| Mar 16, 2007 | Supplement 5Labeling | Approved | None posted |
| Sep 27, 2006 | Supplement 2Labeling | Approved | None posted |
| Apr 24, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters